MAGI2-AS3 Suppresses MYC Signaling to Inhibit Cell Proliferation and Migration in Ovarian Cancer Through Targeting MiR-525-5p/MXD1 Axis

Overview

Journal Cancer Med

Specialty Oncology

Date 2020 Jul 19

PMID 32681706

Citations 18

Authors

Hua Chang

Xue Zhang

Baixue Li

Xiangkai Meng

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OV) is one of the most lethal gynecological malignance in females, and usually diagnosed at advanced stages. Long noncoding RNAs (lncRNAs) exhibit their crucial functions in modulatory mechanisms of cancers. Substantive studies have proven the anti-tumor role of MAGI2-AS3 in multiple cancers, but the physiological functions of MAGI2-AS3 in OV need more detailed explanations. The current study corroborated that overexpression of MAGI2-AS3 executed inhibitory activity in OV via hindering cell proliferation, cell cycle, migration as well as invasion while promoted apoptosis. Moreover MAGI2-AS3 bound with miR-525-5p and negatively regulated the expression of miR-525-5p. Further studies testified that MXD1 was a downstream target of miR-525-5p and the competing relationship between MAGI2-AS3 and MXD1 were confirmed by RNA pull down. Based on the combination between MAX and MYC, we analyzed the effects of MAGI2-AS3 on MXD1 and MYC, unveiling the competing relationship between MXD1 and MYC for binding to MAX. Finally, we constructed rescue assays to certify that MAGI2-AS3 suppressed the course of OV via enhancing MXD1 expression. In summary, MAGI2-AS3 repressed the progression of OV by targeting miR-525-5p/MXD1 axis, offering a novel insight into understanding OV at the molecular level.

Citing Articles

MAGI2-AS3 hypermethylated in promoter region promotes migration and invasion of head and neck squamous cell carcinoma via miRNA-31-5p/AR axis.

Yue K, Zhang T, Wang H, Wang B, Mu Y, Li H Transl Oncol. 2024; 52():102223.

PMID: 39644822 PMC: 11667182. DOI: 10.1016/j.tranon.2024.102223.

Ten Hypermethylated lncRNA Genes Are Specifically Involved in the Initiation, Progression, and Lymphatic and Peritoneal Metastasis of Epithelial Ovarian Cancer.

Braga E, Burdennyy A, Uroshlev L, Zaichenko D, Filippova E, Lukina S Int J Mol Sci. 2024; 25(21).

PMID: 39519394 PMC: 11547154. DOI: 10.3390/ijms252111843.

The roles of long non-coding RNAs in Alzheimer's disease diagnosis, treatment, and their involvement in Alzheimer's disease immune responses.

Wu X, Xia P, Yang L, Lu C, Lu Z Noncoding RNA Res. 2024; 9(3):659-666.

PMID: 38577023 PMC: 10987299. DOI: 10.1016/j.ncrna.2024.03.008.

Identification and Interaction Analysis of Molecular Markers in Pancreatic Ductal Adenocarcinoma by Bioinformatics and Next-Generation Sequencing Data Analysis.

Giriyappagoudar M, Vastrad B, Horakeri R, Vastrad C Bioinform Biol Insights. 2023; 17:11779322231186719.

PMID: 37529485 PMC: 10387711. DOI: 10.1177/11779322231186719.

Fucoxanthin suppresses the malignant progression of ovarian cancer by inactivating STAT3/c-Myc signaling.

Zhang Z, Wang Y, Li J Am J Transl Res. 2023; 15(4):2528-2540.

PMID: 37193140 PMC: 10182483.

References

Chen X, Zhu M, Wang S . Expression of long non-coding RNA MAGI2‑AS3 in human gliomas and its prognostic significance. Eur Rev Med Pharmacol Sci. 2019; 23(8):3455-3460. DOI: 10.26355/eurrev_201904_17710. View

Gao Y, Shan N, Zhao C, Wang Y, Xu F, Li J . LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells. Int J Clin Exp Pathol. 2015; 8(5):4923-32. PMC: 4503057. View

. Ovarian Cancer. Am Fam Physician. 2016; 93(11):Online. View

Yang Y, Yang H, Xu M, Zhang H, Sun M, Mu P . Long non-coding RNA (lncRNA) MAGI2-AS3 inhibits breast cancer cell growth by targeting the Fas/FasL signalling pathway. Hum Cell. 2018; 31(3):232-241. DOI: 10.1007/s13577-018-0206-1. View

Zou A, Liu R, Wu X . Long non-coding RNA MALAT1 is up-regulated in ovarian cancer tissue and promotes SK-OV-3 cell proliferation and invasion. Neoplasma. 2016; 63(6):865-872. DOI: 10.4149/neo_2016_605. View

Dong L, Hui L . HOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3. Med Sci Monit. 2016; 22:325-31. PMC: 4750754. DOI: 10.12659/msm.894913. View

Yu H, Xu Y, Zhang D, Liu G . Long noncoding RNA LUCAT1 promotes malignancy of ovarian cancer through regulation of miR-612/HOXA13 pathway. Biochem Biophys Res Commun. 2018; 503(3):2095-2100. DOI: 10.1016/j.bbrc.2018.07.165. View

Hu W, Jin P, Ding C, Liu W . miR-19a/b modulates lung cancer cells metastasis through suppression of MXD1 expression. Oncol Lett. 2016; 12(3):1901-1905. PMC: 4998008. DOI: 10.3892/ol.2016.4881. View

Chang H, Zhang X, Li B, Meng X . MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis. Cancer Med. 2020; 9(17):6377-6386. PMC: 7476821. DOI: 10.1002/cam4.3126. View

10.

Pujade-Lauraine E . New treatments in ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii57-viii60. DOI: 10.1093/annonc/mdx442. View

11.

Sung H, Yang S, Ju W, Ahn J . Aberrant epigenetic regulation of GABRP associates with aggressive phenotype of ovarian cancer. Exp Mol Med. 2017; 49(5):e335. PMC: 5454450. DOI: 10.1038/emm.2017.62. View

12.

Liu X, Yu Y, Zhang J, Lu C, Wang L, Liu P . HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response. Cell Physiol Biochem. 2018; 48(4):1505-1518. DOI: 10.1159/000492260. View

13.

K Au K, Josahkian J, Francis J, Squire J, Koti M . Current state of biomarkers in ovarian cancer prognosis. Future Oncol. 2015; 11(23):3187-95. DOI: 10.2217/fon.15.251. View

14.

Cao Y, Shi H, Ren F, Jia Y, Zhang R . Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer. Exp Cell Res. 2017; 359(1):185-194. DOI: 10.1016/j.yexcr.2017.07.030. View

15.

Chen F, Chen H, Ke S, Zheng L, Zheng X . SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer. Neoplasma. 2018; 65(6):915-924. DOI: 10.4149/neo_2018_180122N48. View

16.

Cheng D, Xiang Y, Ji L, Lu X . Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. Tumour Biol. 2015; 36(2):479-88. DOI: 10.1007/s13277-015-3093-z. View

17.

Chen M, Liu L . MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C/ZEB1/2 Signal Axis. Dig Dis Sci. 2019; 65(8):2442-2451. DOI: 10.1007/s10620-019-05916-9. View

18.

Zhang X, Zhao H, Zhang Y, Yang X, Zhang J, Yi M . The MicroRNA-382-5p/MXD1 Axis Relates to Breast Cancer Progression and Promotes Cell Malignant Phenotypes. J Surg Res. 2019; 246:442-449. DOI: 10.1016/j.jss.2019.09.018. View

19.

Poliseno L, Pandolfi P . PTEN ceRNA networks in human cancer. Methods. 2015; 77-78:41-50. DOI: 10.1016/j.ymeth.2015.01.013. View

20.

Du W, Feng Z, Sun Q . LncRNA LINC00319 accelerates ovarian cancer progression through miR-423-5p/NACC1 pathway. Biochem Biophys Res Commun. 2018; 507(1-4):198-202. DOI: 10.1016/j.bbrc.2018.11.006. View